RhumbLine Advisers’s Forma Therapeutics Holdings, Inc. Common Stock FMTX Stock Holding History

RhumbLine Advisers’s Portfolio FMTX Stock Details FMTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-64,945	Closed	-$1.3M	–	3076
2022 Q3	$1.3M	Buy	64,945 +6,213	+11%	+$81.9K	﹤0.01%	2004
2022 Q2	$405K	Buy	58,732 +15,182	+35%	+$107K	﹤0.01%	2606
2022 Q1	$405K	Sell	43,550 -1,373	-3%	-$14.6K	﹤0.01%	2515
2021 Q4	$639K	Buy	44,923 +532	+1%	+$9.2K	﹤0.01%	2409
2021 Q3	$1.03M	Buy	44,391 +1,875	+4%	+$44.3K	﹤0.01%	2218
2021 Q2	$1.06M	Buy	42,516 +11,176	+36%	+$300K	﹤0.01%	2219
2021 Q1	$878K	Buy	31,340 +11,506	+58%	+$415K	﹤0.01%	2243
2020 Q4	$692K	Buy	19,834 +2,201	+12%	+$95.8K	﹤0.01%	2306
2020 Q3	$879K	Buy	+17,633	New	+$713K	﹤0.01%	2043

RhumbLine Advisers's FMTX Position: Q4 2022 in Review

RhumbLine Advisers sold out of Forma Therapeutics Holdings, Inc. Common Stock (FMTX) in Q4 2022, closing a stake of 64,945 shares — an estimated $1.3M sold.

RhumbLine Advisers first reported a position in FMTX in Q3 2020 and held it in 9 quarters. The position peaked at $1.3M in Q3 2022. 0 funds tracked by Wall St. Rank hold FMTX as of Q4 2022.

RhumbLine Advisers reported no remaining Forma Therapeutics Holdings, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
RhumbLine Advisers sold 64,945 Forma Therapeutics Holdings, Inc. Common Stock shares in Q4 2022, an estimated $1.3M.
RhumbLine Advisers first reported a position in Forma Therapeutics Holdings, Inc. Common Stock in Q3 2020 and held it in 9 quarters.
RhumbLine Advisers's Forma Therapeutics Holdings, Inc. Common Stock position peaked at $1.3M in Q3 2022.
0 funds tracked by Wall St. Rank held Forma Therapeutics Holdings, Inc. Common Stock as of Q4 2022.

Based on RhumbLine Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.